Virtual Library
Start Your Search
E.D. Ricardo
Author of
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-113 - Neutrophil to Lymphocyte Ratio (NLR) at Diagnosis as a Prognostic Marker in Patients with Stage IV Non-Small Cell Lung Cancer (ID 1286)
09:30 - 09:30 | Author(s): E.D. Ricardo
- Abstract
Background:
Systemic inflammation has been linked with cancer development, cancer cachexia and poor outcome. Neutrophil to lymphocyte ratio (NLR), an index of systemic inflammation, has been associated with worse survival for many types of cancer. The aim of this study is to investigate the clinical significance of the blood NLR as a prognostic factor in non-small cell lung cancer (NSCLC) patients.
Methods:
We retrospectively reviewed the medical charts of patients with metastatic NSCLC, diagnosed between Jan 1st 2011 and July 30th 2014, from a single Brazilian institution. Data on prognostic factors such as histology, gender, performance status, comorbidities and type of treatment were collected. The baseline NLR was assessed just before chemotherapy treatment initiation. NLR was defined as the ratio between the absolute neutrophil and lymphocyte counts. Associations between clinical variables and NLR were tested with Chi-square or exact Fisher´s test. Overall survival (OS) was calculated by the Kaplan–Meier method. Curves were compared using the log-rank test. Multivariate analysis was performed using Cox regression to assess independent patient characteristics associated with OS, and included in the model all variables with p < 0.05 on univariate analysis. All analysis were considered statistically significant when p < 0.05.
Results:
A total of 170 patients were included in the study. Median age was 63.4 years, 54.1% were male, 80.6% had adenocarcinoma, 17.6% had mutated EGFR, 47.6% were former smoker, and 78.2% had ECOG ≤ 1. Median NLR was 4.6. NLR > 4.6 was associated with SNC metastasis. Median follow-up time was 19.64 months and median overall survival was 13.7 months. Patients with NLR > 4.6 had a worse survival. OS was 22.27 months versus 7.03 months (p < 0.001) for patients with NLR ≤ 4.6 and NLR > 4.6, respectively. In multivariate analysis, the NLR remained as an independent prognostic factor for worse OS after adjusting for sex, histology, tumor size and performance status.
Conclusion:
Elevated NLR at diagnosis is an independent predictor of poor OS in patients with advanced NSCLC
